Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25577350

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

Author
LA-BECK, Ninh M1 ; ZAMBONI, Beth A2 8 ; GABIZON, Alberto3 ; SCHMEEDA, Hilary3 ; AMANTEA, Michael4 ; GEHRIG, Paola A5 ; ZAMBONI, William C1 6 7
[1] UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[2] Department of Mathematics, Carlow University, Pittsburgh, PA 15213, United States
[3] Department of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, POB 3235, 91031 Jerusalem, Israel
[4] Department of Clinical Pharmacology, Pfizer, Inc., 10578 Science Center Drive, CB 10, San Diego, CA 92121, United States
[5] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[6] Molecular Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[7] Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[8] Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
Source

Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 43-50, 8 p ; ref : 28 ref

CODEN
CCPHDZ
ISSN
0344-5704
Scientific domain
Medical oncology; Pharmacology drugs
Publisher
Springer, Heidelberg
Publication country
Germany
Document type
Article
Language
English
Author keyword
Doxil Doxorubicin Liposomal Monocytes Pharmacokinetics Reticuloendothelial system Variability
Keyword (fr)
Anticancéreux Doxorubicine Forme pégylée Homme Liposome Malade Monocyte Pharmacocinétique Système réticuloendothélial Variabilité Anthracyclines DNA topoisomerase (ATP-hydrolysing) Enzyme Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases
Keyword (en)
Antineoplastic agent Doxorubicin Pegylated form Human Liposome Patient Monocyte Pharmacokinetics Reticuloendothelial system Variability Anthracyclins DNA topoisomerase (ATP-hydrolysing) Enzyme Topoisomerase II inhibitor Enzyme inhibitor Isomerases
Keyword (es)
Anticanceroso Doxorubicina Forma pegilada Hombre Liposoma Enfermo Monocito Farmacocinética Sistema reticuloendotelial Variabilidad Antraciclinas DNA topoisomerase (ATP-hydrolysing) Enzima Inhibidor topoisomerase II Inhibidor enzima Isomerases
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents

Discipline
Pharmacological treatments
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
25577350

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web